Predicting recurrence with progesterone receptor testing using MammaTyper®
One of our four key goals for clinical validation in 2024 is to demonstrate that progesterone receptor (PR) testing with MammaTyper® could be used for predicting risk of recurrence. In this article, we assess the current role of PR, where IHC testing falls short, and how MammaTyper® could provide a reliable, more accessible option for risk scoring.
PR – the forgotten marker?
In breast cancer testing, progesterone receptor (PR) is sometimes considered the ‘forgotten marker’. Unlike ER or HER2, there are no treatments in current clinical practice linked to the presence or absence of PR. As a res...